Thomas McMurry

Tom joined the OTD in January 2018 as Director, Business Development.  His responsibilities include the commercialization of life science technologies developed at the Boston University School of Medicine, the Goldman School of Dental Medicine, the School of Public Health, Boston Medical Center, and related departments on the Charles River Campus (Chemistry, Biology, etc.).

Tom brings 25 years of senior R&D leadership experience in early stage life sciences companies to the business development role at OTD. Most recently, he served as CEO at WntRx Pharmaceuticals, a preclinical-stage company advancing novel peptide inhibitors of BCL-9/beta-catenin for treatment of metastatic colorectal cancer.  Prior to joining WntRx, he was CEO at Collagen Medical, a molecular imaging company focused on developing thrombosis- and fibrosis-targeted contrast agents. Tom co-founded the GPCR platform company Anchor Therapeutics where he was senior vice president, preclinical R&D.   He also served as vice president of research at EPIX Pharmaceuticals where he co-invented the vascular imaging agent Ablavar® and drove the expansion of the company’s proprietary technology platform into new areas.

Tom began his career as a staff fellow in radioimmunotherapy at the NIHNational Institutes of Health/NCI in Bethesda, Maryland. He holds a BS from Penn State, a PhD in bioorganic chemistry from the University of Michigan, and performed postdoctoral studies at the University of California, Berkeley. Tom is a MassConnect mentor for MassBio and is a member of Penn State’s Eberly College of Science Biotechnology Advisory Board.